Compare Glenmark Pharma with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs FULFORD INDIA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA FULFORD INDIA GLENMARK PHARMA/
FULFORD INDIA
 
P/E (TTM) x 11.9 398.8 3.0% View Chart
P/BV x 1.7 6.2 27.4% View Chart
Dividend Yield % 0.6 0.1 670.7%  

Financials

 GLENMARK PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
FULFORD INDIA
Mar-14
GLENMARK PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs712942 75.5%   
Low Rs484450 107.5%   
Sales per share (Unadj.) Rs349.6691.4 50.6%  
Earnings per share (Unadj.) Rs32.811.5 286.0%  
Cash flow per share (Unadj.) Rs44.315.4 288.6%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.30.3 116.5%  
Book value per share (Unadj.) Rs198.6380.0 52.3%  
Shares outstanding (eoy) m282.173.90 7,235.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.71.0 169.8%   
Avg P/E ratio x18.260.7 30.0%  
P/CF ratio (eoy) x13.545.3 29.7%  
Price / Book Value ratio x3.01.8 164.3%  
Dividend payout %6.117.4 35.0%   
Avg Mkt Cap Rs m168,6252,714 6,212.2%   
No. of employees `00012.00.4 2,711.0%   
Total wages/salary Rs m20,561505 4,071.4%   
Avg. sales/employee Rs Th8,196.06,073.0 135.0%   
Avg. wages/employee Rs Th1,708.11,137.4 150.2%   
Avg. net profit/employee Rs Th768.5100.7 763.3%   
INCOME DATA
Net Sales Rs m98,6552,696 3,658.8%  
Other income Rs m2,081125 1,659.8%   
Total revenues Rs m100,7362,822 3,569.9%   
Gross profit Rs m15,858-46 -34,177.0%  
Depreciation Rs m3,25915 21,441.4%   
Interest Rs m3,34610 35,220.0%   
Profit before tax Rs m11,33554 20,873.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,75610 39,129.2%   
Profit after tax Rs m9,25045 20,693.3%  
Gross profit margin %16.1-1.7 -934.1%  
Effective tax rate %33.117.7 187.5%   
Net profit margin %9.41.7 565.6%  
BALANCE SHEET DATA
Current assets Rs m66,9681,738 3,852.5%   
Current liabilities Rs m40,211545 7,382.2%   
Net working cap to sales %27.144.3 61.3%  
Current ratio x1.73.2 52.2%  
Inventory Days Days8348 171.9%  
Debtors Days Days814 1,886.2%  
Net fixed assets Rs m33,32212 280,015.1%   
Share capital Rs m28239 723.6%   
"Free" reserves Rs m55,7701,443 3,864.8%   
Net worth Rs m56,0521,482 3,782.2%   
Long term debt Rs m35,7380-   
Total assets Rs m132,8882,077 6,399.0%  
Interest coverage x4.46.7 65.3%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.71.3 57.2%   
Return on assets %9.52.6 363.2%  
Return on equity %16.53.0 547.1%  
Return on capital %17.84.3 413.8%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m62,99817 366,269.8%   
Fx outflow Rs m22,859673 3,395.7%   
Net fx Rs m40,140-656 -6,119.2%   
CASH FLOW
From Operations Rs m13,24290 14,713.0%  
From Investments Rs m-6,990105 -6,682.5%  
From Financial Activity Rs m-7,387-14 52,392.9%  
Net Cashflow Rs m-2,971181 -1,645.9%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 6.9 3.8 181.6%  
FIIs % 34.4 0.1 34,400.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.2 49.5%  
Shareholders   56,727 4,783 1,186.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ELDER PHARMA  TTK HEALTHCARE  ORCHID PHARMA LTD  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS